Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness

Journal of Clinical Psychopharmacology

Volumn 18, Issue 5, 1998, Pages 404-413

  Pazzaglia, Peggy J ^a,b   Post, Robert M ^a   Ketter, Terence A ^c   Callahan, Ann M ^d   Marangell, Lauren B ^e   Frye, Mark A ^a   George, Mark S ^f   Kimbrell, Tim A ^g   Leverich, Gabriele S ^a   Cora Locatelli, Gabriela ^a   Luckenbaugh, David ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; DIHYDROPYRIDINE DERIVATIVE; ISRADIPINE; NIMODIPINE; VERAPAMIL;

ARTICLE; BIPOLAR DEPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CALCIUM CHANNEL BLOCKERS; CARBAMAZEPINE; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISRADIPINE; MALE; MIDDLE AGED; NIMODIPINE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 0031690746     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199810000-00009     Document Type: Article

References (77)

1. O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991;159:123-9.
2. Vestergaard P. Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacology 1992;7:249-60.
3. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997;58:470-8.
4. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635-40.
5. Dubovsky SL, Murphy J, Christiano J, Lee C. The calcium second messenger system in bipolar disorders: data supporting new research directions. J Neuropsychiatry Clin Neurosci 1992;4:3-14.
6. Dubovsky SL, Thomas M, Hijazi A, Murphy J. Intracellular calcium signaling in peripheral cells of patients with bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 1994;243:229-34.
7. Meltzer HL. Mode of action of lithium in affective disorders: an influence on intracellular calcium functions. Pharmacol Toxicol 1990;66:84-99.
8. Post RM, Pazzaglia PJ, Ketter TA, Denicoff K, Weiss SRB, Hough C, Chuang D-M, Stein R, Frye M. Carbamazepine and nimodipine in affective illness: efficacy, mechanisms of action, and interactions. In: Montgomery S, Halbreich U, eds. Book IV: pharmacotherapy of mood and cognition. Washington, DC: American Psychiatric Press (in press).
9. Taft WC, Goldenring JR, DeLorenzo RJ. Molecular mechanisms of neuronal excitability: possible involvement of CaM kinase II in seizure activity. In: Ehrlich YH, Lenox RH, Kornecki E, Berry WO, eds. Molecular mechanisms of neuronal responsiveness. New York: Plenum Press, 1987:409-25.
10. Walden J, Grunze H, Bingmann D, Liu Z, Dusing R. Calcium antagonistic effects of carbamazepine as a mechanism of action in neuropsychiatric disorders: studies in calcium dependent model epilepsies. Eur Neuropsychopharmacol 1992;2:455-62.
11. Walden J, Wegerer JV, Roed I, Berger M. Effects of the serotonin-1A agonists buspirone and ipsapirone on field potentials in the hippocampus slice: comparison with carbamazepine and verapamil. Eur Neuropsychopharmacol 1995;5:57-61.
12. Dubovsky SL, Franks RD. Intracellular calcium in affective disorders: a review and an hypothesis. Biol Psychiatry 1983;18:781-97.
13. Carman JS, Wyatt ES, Smith W, Post RM, Ballenger JC. Calcium and calcitonin in bipolar illness. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1984:340-55.
14. Lishman WA. Endocrine diseases and metabolic disorders. In: Organic psychiatry: the psychological consequences of cerebral disorder. 2nd ed. Oxford: Blackwell Scientific Publications, 1987: 447-53.
15. Dubovsky SL, Lee C, Christiano J, Murphy J. Elevated platelet intracellular calcium concentration in bipolar depression. Biol Psychiatry 1991;29:441-50.
16. Kusumi I, Koyama T, Yamashita I. Effect of mood stabilizing agents on agonist-induced calcium mobilization in human platelets. J Psychiatry Neurosci 1994;19:222-5.
17. Dubovsky SL, Christiano J, Daniell LC, Franks RD, Murphy J, Adler L, Baker N, Harris A. Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch Gen Psychiatry 1989;46:632-8.
18. Dubovsky SL. Calcium channel antagonists as novel agents for manic-depressive disorder. In: Schatzberg AF, Nemeroff CB, eds. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1995:377-88.
19. Dose M, Emrich HM, Cording-Tommel C, Von Zerssen D. Use of calcium antagonists in mania. Psychoneuroendocrinology 1986; 11:241-3.
20. Dubovsky SL, Franks RD, Allen S. Calcium antagonists in mania: a double-blind study of verapamil. Psychiatry Res 1986;18:309-20.
21. Hoschl C, Kozeny J. Verapamil in affective disorders: a controlled, double-blind study. Biol Psychiatry 1989;25:128-40.
22. Garza-Trevino ES, Overall JE, Hollister LE. Verapamil versus lithium in acute mania. Am J Psychiatry 1992;149:121-2.
23. Pollack MH, Rosenbaum JF. Verapamil in the treatment of recurrent unipolar depression. Biol Psychiatry 1987;22:779-82.
24. Hoschl C, Vackova J, Janda B. Mood stabilizing effect of verapamil. Bratisl Lek Listy 1992;93:208-9.
25. Janicak PG, Pandey G, Sharma R, Peterson J, Leach A, Davis JM. Verapamil for acute mania; preliminary results from a double-blind, placebo-controlled study [abstract]. Presented at the First International Conference on Bipolar Disorder, Pittsburgh, PA, 23-24 June 1994:46.
26. Walton SA, Berk M, Brook S. Superiority of lithium over verapamil in mania; a randomized, controlled, single-blind trial. J Clin Psychiatry 1996;57:543-6.
27. Freedman DD, Waters DD. "Second generation" dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications. Drugs 1987;34:578-98.
28. Pani L, Kuzmin A, Diana M, De Montis G, Gessa GL, Rossetti ZL. Calcium receptor antagonists modify cocaine effects in the central nervous system differently. Eur J Pharmacol 1990;190:217-21.
29. Pani L, Carboni S, Kusmin A, Gessa GL, Rossetti ZL. Nimodipine inhibits cocaine-induced dopamine release and motor stimulation. Eur J Pharmacol 1990;176:245-6.
30. Dolin SJ, Hunter AB, Halsey MJ, Little HJ. Anticonvulsant profile of the dihydropyridine calcium channel antagonists, nitrendipine and nimodipine. Eur J Pharmacol 1988;152:19-27.
31. Meyer FB, Tally PW, Anderson RE, Sundt TM Jr, Yaksh TL, Sharbrough FW. Inhibition of electrically induced seizures by a dihydropyridine calcium channel blocker. Brain Res 1986;384:180-3.
32. Paczynski RP, Meyer FB, Anderson RE. Effects of the dihydropyridine Ca2+ channel antagonist nimodipine on kainic acid-induced limbic seizures. Epilepsy Res 1990;6:33-8.
33. Vezzani A, Wu HQ, Stasi MA, Angelico P, Samanin R. Effect of various calcium channel blockers on three different models of limbic seizures in rats. Neuropharmacology 1988;27:451-8.
34. Wurpel JN, Iyer SN. Calcium channel blockers verapamil and nimodipine inhibit kindling in adult and immature rats. Epilepsia 1994;35:443-9.
35. Brandt L, Saveland H, Ljunggren B, Andersson KE. Control of epilepsy partialis continuans with intravenous nimodipine. Report of two cases. J Neurosurg 1988;69:949-50.
36. de Falco FA, Bartiromo U, Majello L, Di Geronimo G, Mundo P. Calcium antagonist nimodipine in intractable epilepsy. Epilepsia 1992;33:343-5.
37. Larkin JG, McKee PJ, Blacklaw J, Thompson GG, Morgan IC, Brodie MJ. Nimodipine in refractory epilepsy: a placebo-controlled, add-on study. Epilepsy Res 1991;9:71-7.
38. Brunet G, Cerlich B, Robert P, Dumas S, Souetre E, Darcourt G. Open trial of a calcium antagonist, nimodipine in acute mania. Clin Neuropharmacol 1990;13:224-8.
39. Manna V. Bipolar affective disorders and role of intraneuronal calcium. Therapeutic effects of the treatment with lithium salts and/or calcium antagonist in patients with rapid polar inversion [article in Italian]. Minerva Med 1991;82:757-63.
40. Goodnick PJ. Nimodipine treatment of rapid cycling bipolar disorder [letter]. J Clin Psychiatry 1995;56:330.
41. Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 1993;49:257-72.
42. Montenegro R, Comide E, Castro JM. Nimodipine in the treatment of involutional depressive syndrome. In: Betz E, Deck K, Hoffmeister F, eds. Nimodipine: pharmacological and clinical studies. Stuttgart, Germany: Schattauer, 1985:345-58.
43. Angst J, Merikangas K, Scheidegger P, Wicki W. Recurrent brief depression: a new subtype of affective disorder. J Affect Disord 1990;19:87-98.
44. Montgomery SA, Montgomery D, Baldwin D, Green M. The duration, nature and recurrence rate of brief depressions. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:729-35.
45. Leverich GS, Post RM. Life charting the course of bipolar disorder. Curr Rev Mood Anxiety Disord 1996;1:48-61.
46. Bunney WE Jr, Hamburg DA. Methods for reliable longitudinal observation of behavior. Arch Gen Psychiatry 1963;9:280-94.
47. Squillace K, Post RM, Savard R, Erwin M. Life charting of the longitudinal course of recurrent affective illness. In: Post RM, Ballenger JC, eds. Neurobiology of mood disorders. Baltimore: Williams & Wilkins, 1984:38-59.
48. Kramlinger KG, Post RM. Ultra-rapid and ultradian cycling in bipolar affective illness. Br J Psychiatry 1996;168:314-23.
49. George MS, Jones M, Post RM, Putnam F, Mikalauskas K, Leverich GS. The longitudinal course of affective illness: a mathematical model involving chaos theory. Psychiatry Res (in press).
50. McDermut W, Pazzaglia PJ, Huggins T, Mikalauskas K, Leverich GS, Ketter TA, Bartko J, Post RM. Use of single case analyses in off-on-off-on trials in affective illness: a demonstration of the efficacy of nimodipine. Depression 1995;2:259-71.
51. Tartara A, Galimberti CA, Manni R, Parietti L, Zucca C, Baasch H, Caresia L, Muck W, Barzaghi N, Gatti G. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol 1991; 32:335-40.
52. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159-71.
53. Hough CJ, Irwin RP, Gao X-M, Rogawski MA, Chuang D-M. Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells. J Pharmacol Exp Ther 1996;276:143-9.
54. Post RM, Chuang D-M. Mechanism of action of lithium: comparison and contrast with carbamazepine. In: Birch NJ, ed. Lithium and the cell: pharmacology and biochemistry. London: Academic Press, 1991:199-241.
55. Post RM, Weiss SRB, Chuang D-M. Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J Clin Psychopharmacol 1992;12[suppl 1]:23S-35S.
56. Post RM, Weiss SRB, Chuang D-M, Ketter TA. Mechanisms of action of carbamazepine in seizure and affective disorders. In: Joffe RT, Calabrese JR, eds. Anticonvulsants in mood disorders. New York: Marcel Dekker, Inc., 1994:43-92.
57. Murphy TH, Worley PF, Baraban JM. L-type voltage-sensitive calcium channels mediate synaptic activation of immediate early genes. Neuron 1991;7:625-35.
58. Fukunaga K, Soderling TR. Activation of Ca2+/calmodulin-dependent protein kinase II in cerebellar granule cells by N-methyl-D-aspartate receptor activation. Mol Cell Neurosci 1990;1:133-8.
59. Bading H, Ginty DD, Greenberg ME. Regulation of gene expression in hippocampal neurons by distinct calcium signaling pathways. Science 1993;260:181-6.
60. Frye MA. The increasing use of polypharmacy for refractory mood disorders: twenty-five years of study [abstract NR312]. American Psychiatric Association New Research Program and Abstracts, American Psychiatric Association Annual Meeting, New York, NY, 4-9 May 1996. Washington, DC: APA Press, 1996:151-2.
61. Czyrak A, Mogilnicka E, Maj J. Dihydropyridine calcium channel antagonists as antidepressant drugs in mice and rats. Neuropharmacology 1989;28:229-33.
62. de Jonge M, Freidl A, de Vry J. CNS pharmacology of nimodipine: antidepressant effects, drug discrimination and Ca2+ imaging. In: Scriabine A, Janis RA, Triggle DJ, eds. Drugs in development, vol. 2: Ca2+ antagonists in the CNS. Branford: Neva Press, 1993:165-74.
63. Mogilnicka E, Czyrak A, Maj J. Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test: antidepressants facilitate nifedipine action. Eur J Pharmacol 1987;138:413-6.
64. Mogilnicka E, Czyrak A, Maj J. BAY K 8644 enhances immobility in the mouse behavioral despair test, an effect blocked by nifedipine. Eur J Pharmacol 1988;151:307-11.
65. Martin P, Laurent S, Mussol J, Childs M, Puech AJ. Effects of dihydropyridine drugs on reversal by imipramine of helpless behavior in rats. Eur J Pharmacol 1989;162:185-8.
66. Geoffroy M, Mogilnicka E, Nielsen M, Rafaelsen OJ. Effect of nifedipine on the shuttlebox escape deficit induced by inescapable shock in the rat. Eur J Pharmacol 1988;154:277-83.
67. Nowak G, Paul IA, Popik P, Young A, Skolnick P. Ca2+ antagonists effect an antidepressant-like adaptation of the NMDA receptor complex. Eur J Pharmacol 1993;247:101-2.
68. Kramer MS, Caputo K, DiJohnson C, Maldonado L, Mirow A, Sheves P, Sholevar F. Negative trial of nifedipine in depression [letter]. Biol Psychiatry 1988;24:958-9.
69. Hullett FJ, Potkin SG, Levy AB, Ciasca R. Depression associated with nifedipine-induced calcium channel blockade. Am J Psychiatry 1988;145:1277-9.
70. Lyndon RW, Johnson G, McKeough G. Nifedipine-induced depression [letter]. Br J Psychiatry 1991;159:447-8.
71. Steardo L, Barone P, Hunnicutt E. Carbamazepine lowering effect on CSF somatostatin-like immunoreactivity in temporal lobe epilepsy. Acta Neurol Scand 1986;74:140-4.
72. Pazzaglia PJ, George MS, Post RM, Rubinow DR, Davis C. Nimodipine increases CSF somatostatin in affectively ill patients. Neuropsychopharmacology 1995;13:75-83.
73. Rubinow DR, Davis CL, Post RM. Somatostatin in neuropsychiatric disorders. In: Weil C, Mullen EE, Thornen MO, eds. Somatostatin: basic and clinical aspects of neuroscience. Vol. 4. Berlin: Springer-Verlag, 1992:29-42.
74. Vecsei L, Csala B, Widerlov E, Ekman R, Czopf J, Palffy G. Lumbar cerebrospinal fluid concentrations of somatostatin and neuropeptide Y in multiple sclerosis. Brain Res Bull 1990;25: 411-3.
75. Altemus M, Pigott T, L'Heureux F, Davis CL, Rubinow DR, Murphy DL, Gold PW. CSF somatostatin in obsessive-compulsive disorder. Am J Psychiatry 1993;150:460-4.
76. Frye MA, Pazzaglia PJ, Luckenbaugh D, Kimbrell TA, Little JT, Dunn RT, George MS, Huggins T, Vanderham L, Leverich GS, Davis C, Rubinow DR, Post RM. Baseline CSF somatostatin predictive of nimodipine treatment response [abstract]. Biol Psychiatry 1997;41[suppl 7]:33S.
77. Ketter TA, Kimbrell TA, George MS, Stein RM, Willis MW, Benson BE, Frye MA, Cora-Locatelli G, Post RM. Baseline hypermetabolism may predict carbamazepine response, and hypometabolism nimodipine response in mood disorders [abstract]. Eur Neuropsychopharmacol 1996;6[suppl 3]:10.